Picture of Biomed Lublin Wytwornia Surowic i Szczepionek SA logo

BML Biomed Lublin Wytwornia Surowic i Szczepionek SA Income Statement

0.000.00%
pl flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapSucker Stock

Annual income statement for Biomed Lublin Wytwornia Surowic i Szczepionek SA, fiscal year end - December 31st, PLN millions except per share, conversion factor applied.

2017
December 31st
2018
December 31st
2019
December 31st
2020
December 31st
2021
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:ARSARSARSARSARS
Standards:
PAS
PAS
PAS
PAS
PAS
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue31.432.339.140.241.2
Cost of Revenue
Gross Profit1416.221.320.622.7
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses26.667.733.434.234
Operating Profit4.85-35.45.725.937.19
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes1.68-38.23.724.315.89
Provision for Income Taxes
Net Income After Taxes0.588-32.42.484.444.25
Net Income Before Extraordinary Items
Net Income0.588-32.42.484.444.25
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income0.588-32.42.484.444.25
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS-0.049-0.220.0440.080.079
Dividends per Share

Or unlock with your email

Or unlock with your email